EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

Lazertinib is an oral, highly selective, third-generation EGFR tyrosine kinase inhibitor that can penetrate the brain, and amivantamab is a bispecific antibody targeting EGFR and mesenchymal ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...